Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

RICHMOND, Calif., April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM RICHMOND, Calif., ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 billion.

Sangamo said in November 2024 that the company only had enough money in the bank to last until the first quarter of 2025. It's not immediately clear how far Lilly’s $18 million cash payment will ...

Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets ...

The latest analyst rating for Sangamo Therapeutics (NASDAQ:SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics reiterated their buy rating. The last upgrade for Sangamo ...

478 average and 33 hits last season. She was unanimous all-Sangamo Conference first team. Need a break? Play the USA TODAY Daily Crossword Puzzle. The senior infielder doled out 53 hits ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...